Distrupol Acquires the Business of Oy Baritec AB
Distrupol, a leading European distributor of thermoplastics and elastomers to the polymer processing industry and an affiliate of GPD Companies, Inc. (“GPD”), today announced that it has entered into an asset purchase agreement with Oy Baritec AB (“Baritec” or the “Company”). The deal is expected to close at the end of April 2022.
Founded in 1994, Baritec is a leading distributor and agent of plastics and plastic additives. The Company provides a broad range of polymers and resins, specialty plastics, adhesives, and plastic additives and color masterbatches. Headquartered in Espoo, Finland, Baritec supplies products to clients in Finland, Estonia, Latvia and Lithuania, with strategic warehouses designed to provide safe and efficient product delivery.
“Baritec has excelled at cooperating closely with customers and principals to provide innovative solutions that meet ever-changing market challenges and needs,” said Richard Orme, Managing Director of Distrupol. “We’re truly excited to welcome Baritec’s team and customer-oriented, solutions-based mindset to the Distrupol business. We look forward to expanding the range and reach of our product and service offerings to our customers, particularly in the Nordic region.”
“We are delighted to become part of the distinguished Distrupol organization, whose values and core beliefs are consistent with ours at Baritec. I am confident that our customers will benefit hugely from the expertise and reach of Distrupol,” said Mr. Antti Puotila, primary owner and Chairman of the Board of Baritec. “We look forward to combining efforts with Distrupol to enhance our customer value proposition and further develop the business that we have so proudly built.”
“The acquisition of the Baritec business by Distrupol further extends the presence of GPD and continues the execution of our growth strategy,” said Paul Tayler, Chief Executive Officer of GPD. “Baritec is highly respected in the industry, and we are fortunate to welcome its team, customers and capabilities into the Distrupol family.”
ABOUT DISTRUPOL
Headquartered in Surrey, England, with broad geographic reach across Europe, Distrupol has provided value-added sales and application development of thermoplastic resins for over 50 years. Through its decades-long relationships with world class supply partners, the company offers a robust array of superior performance products and solutions that meet the needs of diverse end users from leading and emerging industries such as the consumer, medical, automotive and electrical sectors, among others. Distrupol caters to over 1,300 customers across 13 countries with a portfolio of over 4,000 grades of high-quality polymers, including sustainably derived solutions that reduce environmental impact. For more information, visit www.distrupol.com.
ABOUT GPD COMPANIES, INC.
GPD Companies, Inc. is a leading group of global value-added distributors formed by One Rock Capital Partners, LLC. For more information, visit www.gpdcompanies.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220413005379/en/
Contact information
Romelia Hinojosa
GPD Companies, Inc.
+1-936-242-0542
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
QPS Selects Oracle Argus Safety Database to Enhance Pharmacovigilance in Clinical Trials15.1.2026 14:57:00 EET | Press release
QPS Holdings, LLC (QPS), an award-winning contract research organization (CRO) focused on bioanalysis and clinical trials announces the successful implementation of Oracle Argus, a premier pharmacovigilance system designed to support comprehensive safety case management for clinical trials. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115711485/en/ Derek Grimes, EVP, Global Head of Clinical Research at QPS Holdings, LLC. The adoption of the Oracle Argus drug safety platform underscores QPS’s commitment to advancing patient safety, regulatory compliance, and operational excellence across its clients’ clinical drug development programs. Integrating this industry-standard safety platform strengthens QPS’ ability to capture, manage, and report adverse events in accordance with global regulatory requirements. “Ensuring patient safety and data integrity is at the heart of what we do when conducting clinical trials,” said Dere
InterAx and Alveus Announce Strategic Research and Licensing Agreement to Develop Differentiated Therapeutic Candidate for Metabolic Disease15.1.2026 14:30:00 EET | Press release
InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™ discovery platform – designed to optimize candidates toward superior signaling profiles – with Alveus’s deep R&D expertise and leadership in obesity, diabetes, and cardiometabolic disease. While financial terms remain undisclosed, the agreement includes an upfront payment and eligibility for future development, regulatory, and commercial milestones. “We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, CEO of InterAx. “O
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness15.1.2026 14:01:00 EET | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program. The collaboration provides Agenus with strategic capital and committed, long-term biologics manufacturing capacity in the United States to support BOT+BAL clinical development, authorized early access pathways, and commercial supply preparation. As part of the collaboration, Agenus has granted Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka, with Agenus eligible to receive royalties on net sales in those territories. The collaboration, first announced on June 3, 2025, included the following key financial terms: Upfront Consideration: $75 million cash payment to Agenus for transfer of biologics manufac
WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion15.1.2026 14:00:00 EET | Press release
WHOOP, the human performance company, announces a landmark creative partnership with acclaimed designer Samuel Ross MBE, who joins as Global Creative Director, WHOOP x SR_A to lead a multiyear collaboration between the two brands titled PROJECT TERRAIN. The collaboration signals the ongoing evolution of WHOOP from a pioneering wearable technology company into a brand shaping not just the future of personal health but also its intersection with performance fashion and cultural design. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115643104/en/ WHOOP and Samuel Ross MBE Announce Multiyear, Global Creative Partnership, Introducing a New Era in Performance Fashion As the first performance design collaboration for WHOOP, the partnership represents a new chapter for the brand. Under Ross’ direction, PROJECT TERRAIN will deliver a bespoke capsule collection including limited-edition, customized WHOOP bands. The range will also
TNG Digital and EPOS Launch EPOS360 and EPOS360 BlueTap in Malaysia to Help Local SMEs Grow with AI and Unique Payment Capabilities15.1.2026 12:23:00 EET | Press release
TNG Digital Sdn. Bhd. (“TNG Digital”), the operator of Malaysia’s leading digital financial services and lifestyle app, TNG eWallet, and EPOS, the all-in-one SME transformation platform of Ant International, have jointly announced the launch of EPOS360 in Malaysia, with a suite of AI-powered growth tools and unique payment capabilities to support the digitalisation of Malaysian businesses, particularly SMEs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260115763131/en/ [From left] Mr. Sarveswaran Raja Gopal, Chief Commercial Officer of TNG Digital; Mr. Alan Ni, Chief Executive Officer of TNG Digital; [middle] En. Anuar Fariz Fadzil, Chief Executive Officer of Malaysia Digital Economy Corporation (MDEC); Mr. Gary Liu, Chief Executive Officer of Antom and Senior Vice President of Ant International; and Mr. Alan Wang, Chief Executive Officer of EPOS and Vice President of Ant International, at the launch of EPOS360 and EPOS360
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom